Drug intelligence / Profile preview

KH-002

Development stage: Preclinical
Lead developer: HysensBio
Modality: Peptides
Administration: Topical

Overview

KH-002 is a peptide-based therapeutic candidate developed by HysensBio for the treatment of dental caries (tooth decay). It is designed to promote the regeneration of dentin by reactivating odontoblasts, the cells responsible for dentin formation. The drug is based on HysensBio's core technology involving the CPNE7 (Copine-7) protein, which facilitates the differentiation of dental pulp stem cells into functional odontoblasts. By inducing natural tooth repair, KH-002 aims to provide a regenerative alternative to traditional dental fillings.

Beyond the preview

Go deeper on KH-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KH-002.

Explore the full profile